Who is sponsoring NCT04366596?

NCT04366596 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04366596?

Interventions in NCT04366596: Angioplasty with paclitaxel eluting balloon, Angioplasty with plain old balloon.

What condition does NCT04366596 study?

NCT04366596 studies Hypertension, Renovascular.

Is NCT04366596 still recruiting?

NCT04366596 is currently status unknown. Last updated 29 April 2020.

Last reviewed 2020-04-29 · How we verify

NCT04366596

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis

Status unknown Phase 3 Last updated 29 April 2020

What this trial tests

Phase 3 trial testing Angioplasty with paclitaxel eluting balloon in Hypertension, Renovascular in 90 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
1 October 2023

1 October 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	90
Start date	1 October 2019
Primary completion	1 October 2023
Estimated completion	1 October 2023
Sites	1 location across China

Drugs / interventions tested

Angioplasty with paclitaxel eluting balloon
Angioplasty with plain old balloon

Conditions studied

Hypertension, Renovascular — all drugs for Hypertension, Renovascular →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 45, any sex, with Hypertension, Renovascular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy of drug eluting balloon(DEB) for non-atherosclerotic renal artery stenosis will be tested in this study. The intervention group will be treated with paclitaxel eluting balloon. The control group will be treated with plain old balloon(POB). The primary endpoint is efficacy of blood pressure control.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04366596 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 29 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04366596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing